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Background: Our previous studies showed that glioma-associated oncogene (Gli)2 plays an important role in the
proliferation and apoptosis resistance of hepatocellular carcinoma (HCC) cells. The aim of this study was to explore
the clinical significance of Gli2 expression in HCC.
Methods: Expression of Gli2 protein was detected in samples from 68 paired HCC samples, the corresponding
paraneoplastic liver tissues, and 20 normal liver tissues using immunohistochemistry. Correlation of the
immunohistochemistry results with clinicopathologic parameters, prognosis, and the expression of E-cadherin,
N-cadherin, and vimentin were analyzed.
Results: Immunohistochemical staining showed high levels of Gli2 protein expression in HCC, compared with
paraneoplastic and normal liver tissues (P < 0.05). This high expression level of Gli2 was significantly associated with
tumor differentiation, encapsulation, vascular invasion, early recurrence, and intra-hepatic metastasis (P < 0.05).
There was a significantly negative correlation between Gli2 and E-cadherin expression (r = −0.302, P < 0.05) and a
significantly positive correlation between expression of Gli2 and expression of vimentin (r = −0.468, P < 0.05) and
N-cadherin (r = −0.505, P < 0.05). Kaplan-Meier analysis showed that patients with overexpressed Gli2 had
significantly shorter overall survival and disease-free survival times (P < 0.05). Multivariate analysis suggested that
the level of Gli2 expression was an independent prognostic factor for HCC.
Conclusions: Expression of Gli2 is high in HCC tissue, and is associated with poor prognosis in patients with HCC
after hepatectomy.
Keywords: Gli2, Hepatocellular carcinoma, Prognosis, Epithelial-to-mesenchymal transitionBackground
Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy and the third most common cause of
death from cancer worldwide [1,2]. There are an estimated
626,000 to 1,000,000 new cases annually worldwide, with
about half of these occurring in China alone [3,4]. Despite
advances in surgical and chemotherapeutic approaches,
the survival rate of patients with HCC is as low as 20 to* Correspondence: gyeyxueping@163.com
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reproduction in any medium, provided the or50% at 5 years, even in early-stage HCC after radical resec-
tion [5,6]. Recurrence after treatment remains one of the
most important causes of poor long-term survival. Predic-
tion of tumor carcinogenesis using molecular prognostic
markers might aid in developing more effective thera-
peutic strategies and therefore result in better prognosis.
However, to date, no identified molecular marker has
shown unequivocal prognostic utility in HCC.
The Hedgehog (Hh) signaling pathway regulates body
patterning, cell differentiation, and proliferation during
embryonic development [7,8]. In humans, the Hh signal-
ing pathway consists of three ligands: Shh, Ihh, and Dhh,
which can bind to the transmembrane receptor Patched 1Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathologic characteristics of 68 patients







































Abbreviations: AFP, alpha fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C
virus; TMN, tumor, node, metastasis.
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(Smo) is released, signals are transduced to the nucleus,
and these converge on three Gli zinc finger transcription
factors: Gli1, Gli2, and Gli3 [9]. Aberrant activation of the
Hh pathway has recently been reported in various human
cancers, including basal cell carcinoma, gastrointestinal
malignancies, and breast, prostate, pancreatic, and lungcancers [10-16]. In addition, the Hh pathway cascade
cross-talks with the WNT, EGF/FGF, and TGF-β/Activin/
Nodal/BMP signaling cascades, which are implicated in
epithelial-to-mesenchymal transition (EMT) through re-
pression of E-cadherin and activation of N-cadherin,
therefore, the Hh pathway is associated with invasion and
metastasis of tumors [17].
Previous studies have shown that components of the
Hh pathway are indicators for poor survival in bladder
cancer, oral and esophageal squamous cell carcinoma,
and ovarian, colon and breast cancers [18-23]. Of the
three Gli transcriptional factors, Gli2 is a strong positive
activator of downstream target genes, and it can induce
Gli1 expression independent of Hh signaling [24]. The
Gli2 protein has been reported to have high expression
levels in HCC cell lines and human HCC tissues [25-28].
Our previous work showed that small hairpin (sh)RNA-
mediated silencing of the Gli2 gene inhibits proliferation
by inducing cell-cycle arrest at G1 phase in the HCC
SMMC-7721 cell line. Moreover, knockdown of Gli2
enhanced SMMC-7721 to tumor necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL)-induced cell
apoptosis via downregulation of c-FLIP and Bcl-2, con-
sequently leading to induction of caspase-8 or caspase-9
dependent apoptosis pathway [29]. However, there have
been few clinical reports investigating the relationship
between Gli2 protein expression and the postoperative
survival of patients with HCC, or whether Gli2 is rea-
lated to induction of EMT.
In the current study, we examined expression of Gli2
protein in HCC tissue using immunohistochemistry. We
also evaluated the relationship of this expression with
the clinical characteristics, expression of E-cadherin, N-
cadherin, and vimentin, and prognosis to determine
whether the level of Gli2 expression could be used to




The study was approved by the Ethics Committee of the
Second Affiliated Hospital of Guangzhou Medical College
with the following reference number: GY20080216302.
Each patient provided written informed consent before
hepatectomy.
Patients and liver specimens
Samples of primary HCC tissues (n = 68) and correspond-
ing paraneoplastic liver tissue (PLT, taken at 20 mm dis-
tance from the tumor margin) were obtained from
patients (53 men, 15 women, median age 55 years; range
33–78 years) who underwent curative resection at the
Second Affiliated Hospital of Guangzhou Medical College
(Guangzhou, China) between February 2004 and July 2007.
Figure 1 Representative images of Gli2 immunohistochemical staining in human normal liver tissue (NLT), paraneoplastic liver tissue
(PLT), and HCC. (A,E) NLT with negative Gli2 expression. (B,F) PLT with week Gli2 expression. (C,G) HCC with moderate Gli2 expression. (D,H)
HCC with strong Gli2 expression. Original magnification (A-D) × 200 for E-H × 400.
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Curative resection was defined as removal of all
recognizable tumor tissue with a clear microscopic mar-
gin. Specimens were obtained immediately after surgical
resection. The patients were not pretreated with radiother-
apy or chemotherapy before surgery. The control tissues
were 20 samples of normal liver tissue (NLT), which were
acquired from patients who had undergone surgery for
liver trauma. All specimens were fixed in 10% formalin,
and embedded in paraffin wax for immunohistochemical
analysis.
The clinicopathologic variables are shown in Table 1.
Tumor size ranged from 32 to 193 mm, with a median
of 65 mm. The TNM (tumor, node, metastasis) stage
was determined using the American Joint Committee on
Cancer/International Union Against Cancer tumor clas-
sification system, with 45 patients classified as I or II
and 23 as III or IV. Tumor differentiation was classified
as follows: 16 tumors were well differentiated, 39 were
moderately differentiated, and 13 cases were poorly
differentiated.
Immunohistochemistry
Formalin-fixed, paraffin wax-embedded tissue specimens
were obtained. Serial sections 4 μm thick were prepared
from each sample, then some sections were stained with
hematoxylin and eosin for histologic diagnoses of tumorand non-tumor, while other sections were stained for
Gli2 using the streptavidin–biotin horseradish peroxid-
ase complex method. For the latter, the tissue sections
were dewaxed, rehydrated with a xylene and graded al-
cohol series, and then incubated in 3% hydrogen perox-
ide for 10 minutes to block endogenous peroxidase
activity. Optimal antigen retrieval was carried out in cit-
rate buffer (pH 6.0) for 10 minutes in a microwave oven
to enhance the immunoreactivity, and then sections
were incubated in 10% blocking serum for 30 minutes at
37°C to reduce nonspecific binding. Primary anti-Gli2
polyclonal antibodies (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) were diluted 1:100, and incubated
with the sections at 4°C overnight. Subsequently, the
secondary antibodies (biotinylated goat anti-rabbit im-
munoglobulin) and streptavidin peroxidase complex re-
agent were applied. Finally, the visualization signal was
developed with diaminobenzidine (DAB), and the slides
were counterstained with hematoxylin. Two investigators
blinded to the clinical information evaluated each stained
section.
The Gli2 reaction for Gli2 was graded according to the
staining intensity (0, 1+, 2+, and 3+). The percentages of
Gli2–positive cells were also scored on a four-point scale
as 0 (0%), 1 (1 to 33%), 2 (34 to 66%), and 3 (67 to 100%).
The sum of the intensity and percentage scores was used
as the final Gli2 protein staining score. The staining
Table 2 Correlation between Gli2 expression and
clinicopathologic characteristics in HCC
Characteristics Gli2 expression χ2 P
valueHigh (n=43) Low (n=25)
Gender
Male 33 20 0.097 0.755
Female 10 5
Age, years
≤60 29 14 0.890 0.345
>60 14 11
Virus infection




≤200 20 8 1.374 0.241
>200 23 17
Cirrhosis
Present 30 18 0.038 0.846
Absent 13 7
Tumor size, mm
≤50 26 13 0.837 0.360
>50 15 12
TNM stage
I or II 25 20 3.375 0.066
III or IV 18 5
Tumor differentiation




Solitary 32 22 1.784 0.182
Multiple 11 3
Tumor encapsulation
Intact 11 15 7.930 0.005 *
Absent or not intact 32 10
Vascular invasion
Present 23 6 5.620 0.018 *
Absent 20 19
Early recurrence
Yes 25 8 4.324 0.038 *
No 18 17
Intra-hepatic metastasis
Present 16 5 4.997 0.025 *
Absent 17 20
Variables are presented as number and tested by χ2 or Fisher’s exact test.
* P < 0.05.
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to 4, moderate; 5 to 6, strong [30,31]. For statistical ana-
lyses, scores of 0 to 2 were considered ‘low expression’ and
scores of 3 to 6 were considered ‘high expression’.
Follow-up
The follow-up period was defined as the interval from the
date of operation to that of the last visit or the patient’s
death. Deaths from other causes were treated as censored
cases. After discharge, patients were followed up every
3 months during the first 2 years and every 6 months
thereafter by clinical examination, including measurement
of alpha fetoprotein, ultrasonography and computed tom-
ography (CT). Times of tumor recurrence were recorded,
based on the time of recurrences from the date of hepa-
tectomy, they were classified as early (≤1 year) and late
(>1 year) recurrences. Patients who developed recurrence
were treated with radiofrequency ablation, percutaneous
ethanol injection, or transcatheter arterial chemoemboli-
zation, or with re-resection when necessary. Disease-free
survival (DFS) was defined as the interval from the
operation date to recurrence, and overall survival (OS)
was defined as the interval between the operation date
and death. Follow-up was performed using email and
telephone.
Statistical analysis
The χ2 text or Fisher’s exact test was used to analyze the
relationship between Gli2 expression and the clinico-
pathologic characteristics. DFS and OS were calculated
using the Kaplan-Meier method, and differences were
assessed using the log-rank test. The Cox proportional
hazard regression model was used to examine associa-
tions between the various prognostic factors and sur-
vival. For all tests, a value of P < 0.05 was considered
significant. All statistics were calculated using SPSS soft-
ware (version 16.0; SPSS Inc., Chicago, IL, USA).
Results
Expression of Gli2
Follow-up data were obtained for all 68 patients. All
patients were followed up until November 2010. The
follow-up time ranged from 6 to 79 months, with a me-
dian follow-up time of 52 months.
The immunohistochemical staining identified the Gli2
location in the cytoplasm and/or nucleus of tumor cells,
mainly in the cytoplasm. Gli2 expression in NLT from
hemangiomas and PLT were negative or weakly positive
(Figure 1A,B,E,F), and mainly moderately or strongly
positive in HCC (Figure 1C,D,G,H). Overall, high ex-
pression of Gli2 was recorded in 63.2% (43/68), 11.8%
(8/68), and 10% (2/20) of the biopsies in HCC, PLT, and
NLT samples, respectively. There were significant differ-
ences for Gli2 staining between NL and HCC (P<0.05),
Figure 2 Immunohistochemical staining of Gli2, E-cadherin, N-cadherin, and vimentin in two representative hepatocellular carcinoma
(HCC) cases. (a,c,d,e) Patient 1. Expression of Gli2, N-cadherin and vimentin was positive, whereas E-cadherin was negative. (b,d,f,h) Patient 2.
Expression of Gli2, N-cadherin and vimentin was negative, whereas E-cadherin expression was positive. Original magnification × 400.
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significant difference between NL and PLT (P>0.05).Immunohistochemistry analysis of Gli2 expression and its
relationship with clinicopathologic characteristics
Correlation between the expression levels of Gli2 in HCC
and various clinicopathologic variables are summarized in
Table 2. A high expression level for Gli2 protein was sig-
nificantly correlated with tumor differentiation, encapsula-
tion, vascular invasion, early recurrence, and intra-hepatic
metastasis (P<0.05). There was no significant correlation
between Gli2 expression and gender, age, hepatitis virusserology, AFP level, cirrhosis, tumor size, TNM stage, or
number of tumors (P>0.05).
Association between E-cadherin, N-cadherin, vimentin,
and Gli2 expression in hepatocellular carcinoma
Given the role of Hedgehog signaling in inducing EMT
through multiple regulators, such as Snail, ZEB1, ZEB2,
Twist1, Twist2, and FOXC2, [17] we analyzed the rela-
tionship between Gli2 expression and that of E-cadherin,
N-cadherin and vimentin in the 68 HCC samples. Ex-
pression of Gli2 was negatively correlated with E-cad-
herin, and positively correlated with N-cadherin and
vimentin. Tissue with high expression levels for Gli2 also
Table 3 Association between expression of Gli2 and
expressin of E-cadherin, N-cadherin and vimentin in
patients with hepatocellular carcinoma
Expression
level





High 12 31 6.801 0.009* −0.302
Low 15 10
Vimentin
High 35 8 6.801 0.009* 0.468
Low 7 18
N-cadherin
High 37 6 23.324 0.001* −0.505
Low 7 18
* P < 0.05.
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P < 0.05) and vimentin (r = −0.468, P < 0.05), but low
expression of E-cadherin (r = −0.302, P < 0.05) d Repre-
sentative images are shown in Figure 2 and the statistical
results are listed in Table 3.Survival analysis
We assessed the Kaplan-Meier estimates for the group
with high Gli2 expression and the group with low Gli2
expression. Our results indicated that the median OS for
the two groups were 17 and 58 months, respectively.
The log-rank test showed as significant difference
between the two survival curves; the OS rate of the
group with high Gli2 expression was lower than that of
the group with low Gli2 expression (P < 0.05). Similarly,
the median DFS time for the two groups was 8 and
30 months, respectively, and patients with high Gli2
expression of Gli2 had a significantly shorter DFS
compared with the patients with low Gli2 expression
(P < 0.05) (Figure 3).Figure 3 Overall survival (OS) curves of patients with hepatocellular c
between the groups with high and low expression of Gli2. (A) OS; (B)Univariate and multivariate analyses for the prognostic
value of Gli2 expression
In univariate analysis, the factors significantly associated
with OS were tumor size, TNM stage, differentiation,
tumor encapsulation, vascular invasion, and Gli2 expres-
sion, and those significantly associated with DFS were
tumor size, tumor encapsulation, vascular invasion, and
Gli2 expression (Table 4). Furthermore, multivariate Cox
proportional hazards regression analysis indicated that
in patients with HCC, tumor size, vascular invasion, and
Gli2 expression were independent prognostic factors for
OS, while tumor encapsulation, vascular invasion, and
Gli2 expression were independent predictors for DFS
(P < 0.05) (Table 5).Discussion
Gli2, a transcription factor of the Hh pathway, regulates
expression of downstream target genes, including Gli1,
Bcl-2, c-FLIP, cyclin D1, c-Myc and vascular endothelial
growth factor (VEGF) [32-35], which has previously been
implicated in the development of various human tumors,
such as medulloblastomas, basal cell carcinoma, prostate
and breast cancer, and HCC [28,36-38], Gli2 was report-
edly overexpressed and related to poor survival of patients
with pediatric medulloblastoma. Although high expression
levels of the Gli2 protein has been reported in HCC cell
lines and tissues [25,26,39], the association between Gli2
expression and prognosis in patients with HCC has not
been elucidated. To analyze the role of Gli2 in HCC, we
carried out immunohistochemical staining and found
higher levels of Gli2 protein in HCC tissues compared
with PLT and NLT.
Analyzing the association of Gli2 expression with patho-
logic characteristics in 68 patients with HCC identified a
significant correlation of Gli2 expression with tumor dif-
ferentiation, encapsulation, vascular invasion, early recur-
rence, and intra-hepatic metastasis. Kaplan-Meier analysis
showed that patients with HCC who had high expressionarcinoma (HCC) undergoing hepatectomy were compared
disease-free survival.
Table 4 Univariate analysis of factors associated with
overall survival (OS) and disease-free survival (DFS) of 68
patients with hepatocellular carcinoma
Factor P value
OS DFS
Gender (male versus female) 0.564 0.867
Age (≤60 versus >60 years) 0.430 0.682
Virus (HBV versus HCV and none) 0.410 0.247
AFP (≤200 versus >200 ng/ml) 0.909 0.626
Cirrhosis (absent versus present) 0.313 0.551
Tumor size (≤50 versus >50 mm) 0.005 * 0.001 *
TNM stage (I to II versus III to IV) 0.034 * 0.056
Differentiation (well and moderate versus poor) 0.011 * 0.110
Tumor number (solitary versus multiple) 0.401 0.741
Tumor encapsulation (intact versus absent or not intact) 0.011 * 0.009 *
Vascular invasion (absent versus present) 0.003 * 0.001 *
Gli2 expression (low versus high) 0.005 * 0.017 *
Abbreviations: AFP, alpha fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C
virus; TMN, tumor, node, metastasis.
* P < 0.05.








Tumor size 0.002* 2.509 1.414 to 4.454
TNM stage NS — —




Vascular invasion 0.004* 2.305 1.304 to 4.073
Gli2 expression 0.007* 2.239 1.244 to 4.028
Disease-free survival
Tumor size NS — —
Tumor
encapsulation
0.001* 2.763 1.534 to 4.977
Vascular invasion 0.002* 2.516 1.397 to 4.533
Gli2 expression 0.042* 1.917 1.025 to 3.584
Abbreviations: AFP, alpha fetoprotein; NS, not significant.
* P < 0.05.
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with low expression, both for OS and DFS. Multivari-
ate analysis showed that Gli2 was an independent
prognostic factor for both recurrence and survival in
patients with HCC after hepatectomy. Meanwhile,
tumor size and vascular invasion were also independ-
ent prognostic factors for OS, while tumor encap-
sulation and vascular invasion were independent
prognostic factors for DFS. Therefore, the level of pro-
tein expression of Gli2, a novel molecular biomarker,
may be a powerful prognostic indicator for recurrence
and survival of patients with HCC.
Our results showed that high expression of Gli2 was
associated with vascular invasion, early recurrence, and
intra-hepatic metastasis in patients with HCC, suggest-
ing that overexpression of Gli2 contributes to progres-
sion of HCC. Furthermore, the immunohistochemical
results showed a significantly negative correlation be-
tween Gli2 and E-cadherin expression and a signifi-
cantly positive correlation between Gli2 expression and
both vimentin and N-cadherin expression. We speculate
that Gli2 could play an important role in invasion and
metastasis of HCC by inducing EMT.
In previous studies, EMT was characterized by
decreased cell adhesion and increased motility, which
was accompanied by downregulation of E-cadherin and
upregulation of vimentin and N-cadherin [40,41].
Zheng et al. found that Gli1 protein expression was
positively correlated with Shh and S100a4, and nega-
tively correlated with E-cadherin [42]. EMT is regulated
by several transcription factors, including Snail, ZEB1,
ZEB2, Twist1, and Twist2, each of which bind to the E-cadherin promoter region and repress its transcription
[43-49]. The Hh pathway induces JAG2 upregulation
for Notch-CSL-mediated Snal1 upregulation, and also
induces transforming growth factor (TGF)-β secretion
for ZEB1 and ZEB2 upregulation via the TGF-β receptor
and nuclear factor (NF)-κB. TGF-β-mediated downre-
gulation of the microRNAs R-141, 200a, 200b, 200c,
205, and 429 results in upregulation of the ZEB1 and
ZEB2 proteins. Activation of Hh signaling indirectly
leads to EMT through Notch, TGF-β signaling cascades,
and regulatory networks of microRNA [17]. Recently,
Alexaki et al. investigated the role of Gli2 in the inva-
sion and metastasis of melanoma and found that
increased expression of Gli2 was associated in melan-
oma cell lines with loss of E-cadherin expression and
increased capacity to invade a protein gel (Matrigel) and
to form bone metastases in mice [50]. Taken together,
these results indicate that Gli2 might lead to the
increased early recurrence and development of intra-
hepatic metastases of HCC by induction of EMT.Conclusion
Our current findings indicate for the first time that the
expression level of Gli2 is high in HCC tissue, and this
high expression shows a significant association with
poor clinical outcome after hepatectomy and a more ag-
gressive tumor phenotype because it induces EMT
changes. However, further studies are needed to investi-
gate the biochemical mechanisms by which Gli2 induces
EMT of HCC.
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